# Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

> **NCT03473223** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 18226 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **BIOLOGICAL:** Apolipoprotein A-I [human] (apoA-I)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03473223
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2023-02-16
- **Final completion:** 2023-11-17
- **Target enrollment:** 18226 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473223, "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03473223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*